​

Ligand Pharmaceuticals (LGND) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LGND Stock Forecast

Ligand Pharmaceuticals (LGND) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $156.00, with a high of $157.00 and a low of $155.00. This represents a 48.61% increase from the last price of $104.97.

$65 $84 $103 $122 $141 $160 High: $157 Avg: $156 Low: $155 Last Closed Price: $104.97

LGND Stock Rating

Ligand Pharmaceuticals stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (66.67%), 4 Hold (26.67%), 1 Sell (6.67%), and 0 Strong Sell (0.00%).

Buy
Total 15 1 4 10 0 Strong Sell Sell Hold Buy Strong Buy

LGND Price Target Upside V Benchmarks

TypeNameUpside
StockLigand Pharmaceuticals48.61%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$155.00$143.50
Last Closing Price$104.97$104.97$104.97
Upside/Downside-47.66%36.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2533---6
Mar, 2543---7
Feb, 2543---7
Jan, 2543---7
Dec, 2443---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 28, 2025UBS$155.00$122.2326.81%47.66%
Oct 21, 2024Joseph PantginisH.C. Wainwright$157.00$108.3144.95%49.57%
Oct 02, 2024Leland GershellOppenheimer$135.00$99.9535.07%28.61%
Jul 30, 2024Douglas MiehmRBC Capital$130.00$108.7519.54%23.84%
Jul 09, 2024Matt HewittCraig-Hallum$140.00$86.8861.14%33.37%
Jun 28, 2024Joseph PantginisH.C. Wainwright$144.00$82.3374.91%37.18%
Dec 23, 2022Roth Capital$90.00$67.3233.69%-14.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 28, 2025RBC CapitalOutperformOutperformhold
Oct 18, 2024H.C. WainwrightBuyBuyhold
Oct 03, 2024RBC CapitalBuyBuyhold
Oct 02, 2024OppenheimerOutperforminitialise
Aug 12, 2024BenchmarkBuyBuyhold
Jul 30, 2024RBC CapitalBuyBuyhold
Jul 30, 2024RBC CapitalOutperforminitialise
Jul 09, 2024Craig-HallumBuyBuyhold
Jun 28, 2024H.C. WainwrightBuyBuyhold
Dec 23, 2022Roth CapitalBuyBuyhold

Financial Forecast

EPS Forecast

$-1 $1 $3 $5 $7 $9 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.18$3.44$-0.31$3.02$0.50----
Avg Forecast$2.53$3.87$2.79$5.35$5.66$6.07$6.78$7.72$8.54
High Forecast$2.79$4.25$2.85$5.47$6.80$7.57$7.17$7.90$8.74
Low Forecast$2.35$3.59$2.64$4.97$3.47$4.97$6.40$7.17$7.93
Surprise %-107.11%-11.11%-111.11%-43.55%-91.17%----

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$186.42M$277.13M$196.25M$131.31M$167.13M----
Avg Forecast$173.06M$269.76M$203.95M$128.89M$163.37M$187.13M$225.03M$262.60M$302.00M
High Forecast$186.47M$290.66M$207.04M$129.19M$163.82M$187.65M$226.62M$263.92M$307.38M
Low Forecast$163.73M$255.22M$195.53M$128.58M$162.49M$186.43M$223.45M$261.28M$285.48M
Surprise %7.72%2.73%-3.78%1.88%2.31%----

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.98M$57.14M$-5.22M$52.15M$9.07M----
Avg Forecast$-1.78M$51.75M$26.46M$53.82M$91.14M$111.34M$120.52M$133.80M$151.64M
High Forecast$6.67M$63.33M$40.01M$85.52M$120.75M$134.42M$127.40M$140.26M$155.16M
Low Forecast$-10.23M$40.17M$12.92M$22.12M$61.53M$88.26M$113.64M$127.34M$140.86M
Surprise %67.69%10.42%-119.72%-3.09%-90.05%----

LGND Forecast FAQ

Is Ligand Pharmaceuticals stock a buy?

Ligand Pharmaceuticals stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Ligand Pharmaceuticals is a favorable investment for most analysts.

What is Ligand Pharmaceuticals's price target?

Ligand Pharmaceuticals's price target, set by 15 Wall Street analysts, averages $156 over the next 12 months. The price target range spans from $155 at the low end to $157 at the high end, suggesting a potential 48.61% change from the previous closing price of $104.97.

How does Ligand Pharmaceuticals stock forecast compare to its benchmarks?

Ligand Pharmaceuticals's stock forecast shows a 48.61% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Ligand Pharmaceuticals over the past three months?

  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 57.14% Strong Buy, 42.86% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ligand Pharmaceuticals’s EPS forecast?

Ligand Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $6.07, marking a 1114.00% increase from the reported $0.5 in 2024. Estimates for the following years are $6.78 in 2026, $7.72 in 2027, and $8.54 in 2028.

What is Ligand Pharmaceuticals’s revenue forecast?

Ligand Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $187.13M, reflecting a 11.96% increase from the reported $167.13M in 2024. The forecast for 2026 is $225.03M, followed by $262.6M for 2027, and $302M for 2028.

What is Ligand Pharmaceuticals’s net income forecast?

Ligand Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $111.34M, representing an 1127.81% increase from the reported $9.07M in 2024. Projections indicate $120.52M in 2026, $133.8M in 2027, and $151.64M in 2028.